Skip to content

The effect of Curcumin vaginal cream in treatment vulvovaginal candidiasis.

The comparison effect of Curcumin (The active ingredient of Turmeric) and Clotrimazole vaginal cream in treatment vulvovaginal candidiasis.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016111330874N1
Enrollment
94
Registered
2016-12-27
Start date
2016-12-20
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

vulvovaginal candidiasis. Candidiasis of vulva and vagina

Interventions

Intervention 1: curcumin vaginal cream10% , one applicator per day for 1 week. Intervention 2: Clotrimazole vaginal cream1%, one applicator per day for 1 week.
Treatment - Drugs
curcumin vaginal cream10% , one applicator per day for 1 week.
Clotrimazole vaginal cream1%, one applicator per day for 1 week

Sponsors

Vice chancellor for research Ahvaz JundiShapur University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Being married? only sexual partner? Age between 18 -45? Body Mass Index< 30? signs and symptoms of vulvovaginal candidiasis, positive Gram staining smear and culture from vaginal discharge. Exclusion criteria: being pregnancy, lactation and menopausal period; having any vaginal bleeding; recurrent vulvovaginal candidiasis (4 or more vulvovaginal candidiasis in a year); consumption of immunosuppressive drug; women who had used antibiotic for 2 weeks before the study; history of epilepsy, diabetes, heart disease, high blood pressure, thyroid diseases? women who had used other vaginal creams or suppositories for 1 week before the study; women who had used systemic antifungal drugs for 4 weeks before the study; existence of other vaginal infections; consumption of oral contraceptive.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Vaginal discharge. Timepoint: Baseline, 4-7 days after treatment. Method of measurement: Clinical Examination, observation, and medical history.;Itching. Timepoint: Baseline, 4-7 days after treatment. Method of measurement: history.;Vulva and vaginal Erythma. Timepoint: Baseline, 4-7 days after treatment. Method of measurement: Clinical Examination.;Vulva and vaginal burning. Timepoint: Baseline, 4-7 days after treatment. Method of measurement: history.;Vaginal discharge culture results. Timepoint: Baseline, 4-7 days after treatment. Method of measurement: vaginal discharge culture.;Compelet remission. Timepoint: 4-7 days after treatment. Method of measurement: Evauation of clinical symptom's remission and negetive result of vaginal discharge culture.

Secondary

MeasureTime frame
Side effects. Timepoint: 4-7 days after treatment. Method of measurement: question of patient.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Zahra Abbaspoor

Jondishapour University of Medical Sciences

www.Abbaspoor-z762@yahoo.com+98 61 3373 8331

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026